Business Context and Reporting Period
Company: Curis, Inc. (CRIS)
Filing Type: Form 8-K (Current Report)
Date of Report: January 7, 2026
Principal Event: Entry into a Material Definitive Agreement for a Private Investment in Public Equity (PIPE) Financing.
Key Financial Metrics and Capital Structure
This filing details a capital raise rather than operational financial results. Key metrics include:
- Initial Gross Proceeds: Approximately $20.2 million (expected on Closing Date).
- Total Potential Gross Proceeds: Up to approximately $80.8 million (assuming full exercise of warrants).
- Securities Issued:
- 20,195 shares of Series B Convertible Non-Redeemable Preferred Stock.
- Series A, B, and C Warrants to purchase an aggregate of 80,780,025 shares of Common Stock (26,926,675 shares per series).
- Purchase Price: $1,000.00 per "Security" (one share of Preferred Stock plus three warrants).
- Warrant Exercise Price: $0.75 per share.
- Use of Proceeds: Research and development, general corporate expenses, and working capital.
Material Changes and Strategic Developments
Capital Structure Changes: The Company is issuing new Series B Preferred Stock and warrants, which will dilute existing shareholders upon conversion or exercise. The Preferred Stock converts to Common Stock only after stockholder approval and Nasdaq listing rule compliance.
Nasdaq Listing Status: The Company received a delisting notice in August 2025 for failing to meet the $35 million Market Value of Listed Securities (MVLS) requirement. It obtained an exception until November 14, 2025, and subsequently relied on the sale of its Erivedge business to meet the alternative $2.5 million stockholders' equity requirement. The Company believes the PIPE Financing proceeds will sustain equity above this threshold, though delisting remains a risk if the Panel does not approve compliance.
Operational Focus: The Company is focusing on Phase 2 combination studies of emavusertib in chronic lymphocytic leukemia (CLL) and Phase 1/2 studies in primary central nervous system lymphoma. Monotherapy and combination studies in acute myeloid leukemia (AML) are completed.
Outlook, Risks, and Contingencies
- Cash Runway: Management estimates that existing cash plus initial PIPE proceeds (excluding warrant exercises) will extend the cash runway into 2027.
- Closing Conditions: The financing is subject to customary closing conditions and is expected to close on or about January 8, 2026.
- Registration Rights: The Company must file a registration statement for resale of securities within 45 days of closing. Failure to do so triggers liquidated damages of 1.0% of the investment per 30-day period.
- Warrant Terms:
- Series A: Terminate January 8, 2031.
- Series B: Terminate 30 days after the fifth patient is dosed in the Phase 2 CLL trial, with a potential price reset if the stock price is below the exercise price.
- Series C: Terminate July 8, 2027.
- Risks: No assurance that the PIPE Financing will close, that the Company will regain Nasdaq compliance, or that the cash runway estimate will prove accurate.
Investor Verification Checklist
- Verify the final closing of the PIPE Financing and the actual amount of initial proceeds received.
- Monitor the status of the Nasdaq Hearings Panel decision regarding continued listing compliance.
- Track the timeline for stockholder approval required to convert Series B Preferred Stock into Common Stock.
- Review the Company's cash burn rate to validate the "into 2027" cash runway estimate.
- Confirm the filing and effectiveness of the registration statement for the resale of PIPE securities to avoid liquidated damages.